Cargando…

Glaucoma Cases Following SARS-CoV-2 Vaccination: A VAERS Database Analysis

Background: To counter the rapidly spreading severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), global vaccination efforts were initiated in December 2020. We assess the risk of glaucoma following SARS-CoV-2 vaccination and evaluate its onset interval and clinical presentations in patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Singh, Rohan Bir, Parmar, Uday Pratap Singh, Cho, Wonkyung, Ichhpujani, Parul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9610013/
https://www.ncbi.nlm.nih.gov/pubmed/36298495
http://dx.doi.org/10.3390/vaccines10101630
_version_ 1784819164356018176
author Singh, Rohan Bir
Parmar, Uday Pratap Singh
Cho, Wonkyung
Ichhpujani, Parul
author_facet Singh, Rohan Bir
Parmar, Uday Pratap Singh
Cho, Wonkyung
Ichhpujani, Parul
author_sort Singh, Rohan Bir
collection PubMed
description Background: To counter the rapidly spreading severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), global vaccination efforts were initiated in December 2020. We assess the risk of glaucoma following SARS-CoV-2 vaccination and evaluate its onset interval and clinical presentations in patients. Methods: We performed a retrospective analysis of the glaucoma cases reported to the Vaccine Adverse Event Reporting System (VAERS) database between 16 December 2020, and 30 April 2022. We assessed the crude reporting rate of glaucoma, clinical presentations, onset duration, and associated risk factors. Results: During this period, 161 glaucoma cases were reported, with crude reporting rates (per million doses) of 0.09, 0.06, and 0.07 for BNT162b2, mRNA-1273, and Ad26.COV2.S, respectively. The mean age of the patients was 60.41 ± 17.56 years, and 67.7% were women. More than half (56.6%) of the cases were reported within the first week of vaccination. The cumulative-incidence analysis showed a higher risk of glaucoma in patients who received the BNT162b2 vaccines compared with mRNA-1273 (p = 0.05). Conclusions: The incidence of glaucoma following vaccination with BNT162b2, mRNA-1273, or Ad26.COV2.S is extremely rare. Amongst the patients diagnosed with glaucoma, the onset interval of adverse events was shorter among those who received the BNT162b2 and rAd26.COV2.S vaccines compared with mRNA-1273. Most glaucoma cases were reported within the first week following vaccination in female patients and from the fifth to seventh decade. This study provides insights into the possible temporal association between reported glaucoma events and SARS-CoV-2 vaccines; however, further investigations are required to identify the potential causality link and pathological mechanisms.
format Online
Article
Text
id pubmed-9610013
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96100132022-10-28 Glaucoma Cases Following SARS-CoV-2 Vaccination: A VAERS Database Analysis Singh, Rohan Bir Parmar, Uday Pratap Singh Cho, Wonkyung Ichhpujani, Parul Vaccines (Basel) Article Background: To counter the rapidly spreading severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), global vaccination efforts were initiated in December 2020. We assess the risk of glaucoma following SARS-CoV-2 vaccination and evaluate its onset interval and clinical presentations in patients. Methods: We performed a retrospective analysis of the glaucoma cases reported to the Vaccine Adverse Event Reporting System (VAERS) database between 16 December 2020, and 30 April 2022. We assessed the crude reporting rate of glaucoma, clinical presentations, onset duration, and associated risk factors. Results: During this period, 161 glaucoma cases were reported, with crude reporting rates (per million doses) of 0.09, 0.06, and 0.07 for BNT162b2, mRNA-1273, and Ad26.COV2.S, respectively. The mean age of the patients was 60.41 ± 17.56 years, and 67.7% were women. More than half (56.6%) of the cases were reported within the first week of vaccination. The cumulative-incidence analysis showed a higher risk of glaucoma in patients who received the BNT162b2 vaccines compared with mRNA-1273 (p = 0.05). Conclusions: The incidence of glaucoma following vaccination with BNT162b2, mRNA-1273, or Ad26.COV2.S is extremely rare. Amongst the patients diagnosed with glaucoma, the onset interval of adverse events was shorter among those who received the BNT162b2 and rAd26.COV2.S vaccines compared with mRNA-1273. Most glaucoma cases were reported within the first week following vaccination in female patients and from the fifth to seventh decade. This study provides insights into the possible temporal association between reported glaucoma events and SARS-CoV-2 vaccines; however, further investigations are required to identify the potential causality link and pathological mechanisms. MDPI 2022-09-28 /pmc/articles/PMC9610013/ /pubmed/36298495 http://dx.doi.org/10.3390/vaccines10101630 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Singh, Rohan Bir
Parmar, Uday Pratap Singh
Cho, Wonkyung
Ichhpujani, Parul
Glaucoma Cases Following SARS-CoV-2 Vaccination: A VAERS Database Analysis
title Glaucoma Cases Following SARS-CoV-2 Vaccination: A VAERS Database Analysis
title_full Glaucoma Cases Following SARS-CoV-2 Vaccination: A VAERS Database Analysis
title_fullStr Glaucoma Cases Following SARS-CoV-2 Vaccination: A VAERS Database Analysis
title_full_unstemmed Glaucoma Cases Following SARS-CoV-2 Vaccination: A VAERS Database Analysis
title_short Glaucoma Cases Following SARS-CoV-2 Vaccination: A VAERS Database Analysis
title_sort glaucoma cases following sars-cov-2 vaccination: a vaers database analysis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9610013/
https://www.ncbi.nlm.nih.gov/pubmed/36298495
http://dx.doi.org/10.3390/vaccines10101630
work_keys_str_mv AT singhrohanbir glaucomacasesfollowingsarscov2vaccinationavaersdatabaseanalysis
AT parmarudaypratapsingh glaucomacasesfollowingsarscov2vaccinationavaersdatabaseanalysis
AT chowonkyung glaucomacasesfollowingsarscov2vaccinationavaersdatabaseanalysis
AT ichhpujaniparul glaucomacasesfollowingsarscov2vaccinationavaersdatabaseanalysis